| Type | Public |
|---|---|
| Traded as | NASDAQ: ACOR FWB: CDG |
| Industry | Health care Biotechnology |
| Founded | 1995[1] |
| Founder(s) | Ron Cohen |
| Headquarters | Hawthorne, New York, United States |
| Key people | Ron Cohen Andrew R. Blight |
| Products | Zanaflex Ampyra |
| Revenue | |
| Operating income | |
| Net income | |
| Total assets | |
| Total equity | |
| Employees | 328 (February, 2012) [2] |
| Website | Acorda.com |
Acorda Therapeutics (NASDAQ: ACOR, FWB: CDG) is a biotechnology company based in Hawthorne, New York. Acorda Therapeutics develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex and Ampyra in the United States.
|
Contents
|
| This section is empty. You can help by adding to it. |
As of December 31, 2008[update] the members of the board of directors of Acorda Therapeutics are:[4] Ron Cohen, Barry Greene, John Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, Ian F. Smith, and Wise Young.
| This section requires expansion. |
| This section is empty. You can help by adding to it. |
| This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
| This biotechnology article is a stub. You can help Wikipedia by expanding it. |
| This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)